Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

Summary

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

Timeline

Start

2023-10-02

Primary completion

2028-10-27

Completion

2029-05-31

Drugs

Indications